• ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis
• Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging Between 300 and 728 Patients) is Recommended
• Interim Analysis Anticipated to be Completed Before Year-End 2026

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.